Cargando…
Development and pre-clinical testing of a novel hypoxia-activated KDAC inhibitor
Tumor hypoxia is associated with therapy resistance and poor patient prognosis. Hypoxia-activated prodrugs, designed to selectively target hypoxic cells while sparing normal tissue, represent a promising treatment strategy. We report the pre-clinical efficacy of 1-methyl-2-nitroimidazole panobinosta...
Autores principales: | Skwarska, Anna, Calder, Ewen D.D., Sneddon, Deborah, Bolland, Hannah, Odyniec, Maria L., Mistry, Ishna N., Martin, Jennifer, Folkes, Lisa K., Conway, Stuart J., Hammond, Ester M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cell Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8460716/ https://www.ncbi.nlm.nih.gov/pubmed/33910023 http://dx.doi.org/10.1016/j.chembiol.2021.04.004 |
Ejemplares similares
-
Zap‐Pano: a Photocaged Prodrug of the KDAC Inhibitor Panobinostat
por: Troelsen, Kathrin S., et al.
Publicado: (2021) -
CYP450 Enzymes Effect Oxygen-Dependent Reduction of Azide-Based Fluorogenic
Dyes
por: O’Connor, Liam J., et al.
Publicado: (2016) -
Two Color Imaging of
Different Hypoxia Levels in Cancer
Cells
por: Wallabregue, Antoine L. D., et al.
Publicado: (2023) -
Targeting Lysine Deacetylases (KDACs) in Parasites
por: Wang, Qi, et al.
Publicado: (2015) -
KDAC8 with High Basal Velocity Is Not Activated by N-Acetylthioureas
por: Toro, Tasha B., et al.
Publicado: (2016)